Earnings

Benitec Biopharma Q4 EPS $(0.26), Inline

Sep 14, 2026 · 04:09 PM ET· updated 52m ago

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.

Why It Matters

Benitec lost money this quarter, but improved compared to last year. The company is burning less cash, which shows progress even though it is not yet profitable.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BNTC12.09

-0.10 (-0.82%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.